ProteLight Medical Holdings (Hong Kong) Co., Ltd. (abbreviated as "ProteLight Hong Kong"), a wholly-owned subsidiary of Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.  (abbreviated as "Jiangsu ProteLight), was registered in Hong Kong and established in January 2021 . As an important platform for Jiangsu ProteLight’s for international development strategy, ProteLight Hong Kong commits the R&D, the organization of clinical trials and the operations and management of market of the first-in-class innovative antimicrobial and anti-cancer peptides drugs from Jiangsu ProteLight in the countries and regions outside mainland China.

ProteLight Hong Kong commits to resolve the worldwide problems in drug-resistant bacterial infections and cancer area by applying first-in-class innovative antimicrobial and anticancer peptides drugs and contributes to protecting human health. 

The company was established in 2021 and is the first overseas operating entity established by Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.  to engage in new drug research and development. It is also an important hub for ProteLight Pharma to accelerate the internationalization strategy of new drugs and strive to achieve the early benefits of new drugs to patients worldwide. At present, the company's new drug research and development business focuses on core tracks such as antimicrobial peptides and anticancer peptides. The Australian company will rely on its advantages from a globalization perspective to strengthen communication and cooperation with advanced academic, medical institutions, and pharmaceutical companies abroad, providing a unique and comprehensive platform for the globalization of  innovative drugs. Its professional advantages cover product registration, marketing, clinical research, after-sales service, business cooperation, logistics and warehousing, and other aspects. The company has always been committed to the development of domestic innovative drugs internationally and aims to become a multinational pharmaceutical group focused on innovation.

Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. was established in 2006. It is mainly engaged in the preclinical research of peptide drugs and chemical drugs as well as the research and development of innovative disinfection products. It is a wholly-owned R&D subsidiary of Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. The company is located in Changchun High-tech Development Zone and is a national high-tech enterprise. Since its establishment, the company has undertaken the “12th Five-Year”key science and technology project of the National Health Commission’s "Major New Drug Creation", the Ministry of Science and Technology SME Technology Innovation Fund, the Jilin Province’s “International Science and Technology Cooperation Project”, and the Jilin Province’s “Special Fund Project for the Development of the Pharmaceutical and Health Industry”. The company has also  been selected for the Jilin Province Science and Technology Department’s "Major Science and Technology Research Project", and the Jilin Province Science and Technology Innovation Talent Cultivation Plan’s "Youth Research Fund Project". Changchun ProteLight takes innovation as the soul, takes improving the quality of life as its unremitting pursuit, takes scientific rigor as the code of conduct, upholds the research and development of innovative drugs as its mission, continuously develops high-quality new varieties , and creates a benign closed-loop operation model that pays equal attention to production processes, pilot trials, and R&D. 

Nanjing Denovo Pharmaceutical Technology Co., Ltd. is located in the Life Science and Technology Town of Jiangning District, Nanjing. It is a wholly-owned R&D subsidiary of Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. Since its establishment in May 2020, the company has been mainly engaged in the preclinical research and development of first-in-class anti-infection and anti-tumor peptide drugs and chemical drugs. The company currently has a strong R&D team mainly composed of doctors and masters, with advanced experimental conditions and equipment. The company adheres to the spirit of applying what has been learned and overcoming difficulties, adheres to the purpose of developing innovative drugs that meet major clinical needs and sticks to the field of innovative drug research. The company establishes a rigorous and realistic enterprise image and shows the appearance of a pharmaceutical technology enterprise with great business vitality and development prospects.

Jiangsu Putai Pharmaceutical Technology Co., Ltd. was established in 2020 and is a modern high-tech enterprise specializing in the research and development, production, sales, and service of daily health care products. Relying on the strong R&D platform and unique technical advantages of its parent company Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., it strives to build up the competitive advantages in terms of peptide products and technology, and is committed to becoming a benchmark enterprise in the industry, that is close to people's families and improves the quality of healthy life. The company has been adhering to the business philosophy of integrity, standardization, and steady development. As of now, the company has launched over 30 products in four major series, ProteLight® Wenning series, ProteLight® Otty series, ProteLight® Flowtide antimicrobial series, ProteLight® Dr. Germ series, covering antibacterial skin care, oral care, private hygiene and other aspects of personal care and health. In the future, the company will continue to innovate and expand its products and service scopes, develop more new products and series that are beneficial and effective for the public, meet people's increasingly diversified and personalized health needs, and serve public health.